Effect of resveratrol on chronic obstructive pulmonary disease in rats and its mechanism

Yaoxue Xuebao

Volumn 43, Issue 2, 2008, Pages 128-132

  Zhou, Min ^a   He, Jian Lin ^a   Yu, Shu Qin ^a   Zhu, Rui Fang ^a   Lu, Jing ^a   Ding, Fu Yun ^a   Xu, Guang Lin ^a  

^a NANJING NORMAL UNIVERSITY   (China)

Author keywords

Bronchoalveolar lavage fluid; Chronic obstructive pulmonary disease; Intercellular adhesion molecule 1; Resveratrol

Indexed keywords

BLEOMYCIN; INTERCELLULAR ADHESION MOLECULE 1; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; ARTICLE; BLOOD GAS ANALYSIS; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE MODEL; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; LUNG; LUNG COMPLIANCE; LUNG LAVAGE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; RANDOMIZATION; RAT; SMOKING; SPRAGUE DAWLEY RAT;

ANIMALS; BLEOMYCIN; BLOOD GAS ANALYSIS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FEMALE; FORCED EXPIRATORY VOLUME; INTERCELLULAR ADHESION MOLECULE-1; LUNG; LUNG COMPLIANCE; MALE; MAXIMAL MIDEXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SMOKING; STILBENES;

EID: 42149111615     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Anzueto A. Clinical course of chronic obstructive pulmonary disease; review of therapeutic interventions [J]. Am J Med, 2006,119:46-53.
2. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease [J]. Lancet, 2004,364:985-996.
3. Boer WI. Perspectives for cytokines antagonist therapy in COPD [J]. Drug Discov Today, 2005,10:93-106.
4. Szabolcs A, Varga IS, Varga C, et al. Beneficial effect of resveratrol on cholecystokinin-induced experimental pancreatitis [J]. Eur J Pharmacol, 2006, 532: 187-193.
5. Donnelly LE, Newton R, Kennedy GE et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms [J]. Am J Physiol Lung Cell Mol Physiol, 2004,287:L774 -783.
6. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols [J]. Biochem Pharmacol, 2006,72:1439-1452.
7. Culpitt SV, Rogers DF, Fenwick PS, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD [J]. Thorax, 2003, 58: 942-946.
8. Cisneros-Lira J, Gaxiola M, Ramos C, et al. Cigarette smoke exposure potentiates bleomycin-induced lung fibrosis in guinea pigs [J]. Am J Physiol Lung Cell Mol Physiol, 2003,285:L949-956.
9. Wang SJ, Wang XX, Yan J. Resveratrol inhibits proliferation of cultured rat cardiac fibroblasts : correlated with No-cGMP signaling pathway [J]. Eur J Pharmacol, 2007,567:26-35.
10. Alkhalaf M. Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation [J]. Eur J Cancer Prev, 2007,16:334-341.
11. Scarlatti F, Sala G, Ricci C, et al. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase [J]. Cancer Lett, 2007,253:124-130.
12. Abir KG, Bessern M, Ezzedine A, et al. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver [J]. Life Sci, 2007,80:1033-1039.
13. Lu YJ, Yang BF. Resveratrol, a natural ingredient of grape skin; antiarrhythmic efficacy and ionic mechanisms [J]. J Mol Cell Cardiol, 2007,42:S8-9.
14. Ge H, Zhang JF, Guo BS, et al. Resveratrol inhibits expression of EMMPRIN from macrophages [J]. Acta Pharm Sin, 2006,41:625-630.
15. Rahman I, Kilty I. Antioxidant therapeutic targets in COPD [J]. Curr Drug Targets, 2006,7:707 -720.
16. Barnes PJ. Alveolar macrophages as orchestrators of COPD[J]. COPD, 2004,1:59-70.
17. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches [J]. Eur Respir J, 2005,25:1084-1106.
18. Birrell MA, McCluskie K, Wong S, et al. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism [J]. FASEB J, 2005,19:840-841.
19. Kolgazi M, Sener G, Cetinel S, et al. Resveratrol reduces renal and lung injury caused by sepsis in rats [J]. J Surg Res, 2006,134:315-321.
20. Birrell MA, Wong S, Hele DJ, et al. Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-κB pathway activation [J]. Am J Respir Crit Care Med, 2005,172:74-84.
21. Tan YR, Qin XQ, Guan C, et al. Regulatory peptides modulate ICAM-1 gene expression and NF-κB activity in bronchial epithelial cells [J]. Acta Physiol Sin, 2003,55:121-127.
22. Riise GC, Larsson S, Lofdahl CG, et al. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis [J]. Eur Respir J, 1994,7:1673-1677.
23. Veiby OP, Read MA. Chemoresistance. Impact of nuclear factor (NF) -κB inhibition by small interfering RNA enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the NF-κB p65 subunit [J]. Clin Cancer Res, 2004,10:3333-3341.
24. Christman JW, Sadikot RT, Blackwell TS, et al. The role of nuclear factor-kappa B in pulmonary diseases [J]. Chest, 2000,117:1482-1487.
25. Papi A, Luppi F, Franco F, et al. Pathophysiology of exacerbations of chronic obstructive pulmonary disease [J]. Proc Am Thorac Soc, 2006,3:245-251.
26. Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol [J]. Br J Pharmacol, 1999,126:673-680.